ML239 (CID-49843203) is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.

Breast cancer stem cells:1.16 μM.

ML239是一种针对乳腺癌干细胞的有效且选择性的抑制剂，其IC50为1.16 µM。ML239通过激活脂肪酸脱氢酶2（FADS2）的途径，抑制乳腺癌类干细胞。ML239对NCIH661细胞具有细胞毒性，FADS2的敲除降低了ML239的细胞毒性，此外，FADS2抑制剂SC-26196也降低了在癌细胞系（CCLs）中ML239的细胞毒性。

ML239 is dissolved in DMSO.Cancer cell lines (CCLs) are plated at a density of 500 cells/well in white opaque tissue-culture-treated Aurora 1536-well MaKO plates in the provider-recommended growth media using a highly automated platform. Compounds (ML239) are added by acoustic transfer using a Labcyte Echo 555. 24 hours after plating. The effects of small molecules (ML239) are measured over a 16-point concentration range (two-fold dilution) in duplicate. DMSO is used at a constant concentration of 0.33%, including vehicle-only control wells. As a surrogate for viability, cellular ATP levels are assessed 72 hours after compound transfer by addition of CellTiterGlo followed by luminescence measurement using a ViewLux Microplate Imager. Duplicates are averaged and luminescence values normalized to vehicle (DMSO) treatment and background (media-only) wells